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ﬁndings from the TREAT-AF study. J Am Coll Cardiol 2014;64:660–8.REPLY: Increased Mortality by Digoxin in
Patients With Atrial Fibrillation?Dr. de Boer brings up some important design con-
siderations regarding our analysis of the TREAT-AF
(Retrospective Evaluation and Assessment of Ther-
apies in AF) study (1). He correctly argues that there
can be misclassiﬁcation of digoxin exposure in our
design. Our observational study was designed as an
intention-to-treat analysis, comparing the strategies
of use and nonuse of digoxin as initial or early
therapy in patients with newly diagnosed atrial
ﬁbrillation (AF) (1). Although we found that 80% of
patients in the digoxin arm were still on therapy
at 1 year, there is a strong possibility of digoxin
exposure in the control arm after 90 days. How-
ever, we believe this would not represent “mis-
classiﬁcation” in an intention-to-treat design but
rather crossover of therapy. Generally, crossover
would bias toward the null and therefore would not
likely account for the observed difference in
outcomes.
Therapy crossover is common in management of
AF and complicates analysis and interpretation of
randomized trials. Crossover may be motivated by
observed and unobserved confounders, which can
further complicate analysis and may in part explain
the seemingly incongruent results of 2 secondary
analyses of digoxin using the same AFFIRM (AF
Follow-Up Investigation of Rhythm Management)
trial data set (2,3). Separating patients into exposed
and unexposed blocks of person-time without
adjusting for time-varying confounders could exag-
gerate treatment effect (or harm) (4). On the other
hand, contemporary approaches such as marginal
structural models that incorporate time-varying datacan bias toward the null from overadjustment or
model misspeciﬁcation (5).
For these reasons, we elected to study a new dis-
ease cohort using an intention-to-treat design that
evaluated digoxin as an initial treatment strategy.
Our decision to adjust for adherence rather than to
stratify was to account for variation in adherence in
the overall point estimate. We agree that further work
to explore the heterogeneity of treatment effects
across strata of adherence and time course of therapy
would be valuable and complementary.*Mintu P. Turakhia, MD, MAS
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and Paradoxical
Systemic Embolism
Can We Determine High-Risk Characteristics
by Echocardiography?We read with interest the review paper on paradoxi-
cal embolism by Windecker et al. (1). It was sug-
gested, on the basis of available evidence from
published reports, that device closure of patent
foramen ovale (PFO) should be considered in patients
with ﬁrst-time cryptogenic stroke, particularly in
those with high-risk criteria, such as presence of
an atrial septal aneurysm (ASA), large PFO, Eusta-
chian valve, or Chiari network. The viewpoints of
FIGURE 1 Intracardiac Echocardiographic Color Doppler Flow Images With the
Transducer Placed in the Right Atrium for Iatrogenic PFO, Variant Eustachian Valve,
and Chiari Network
(A) No PFO, as indicated by no color ﬂow across the superior limbus (arrow) at baseline.
(B) Iatrogenic PFO (diameter: 3.4 mm), as indicated by color ﬂow imaging with the red
small left-to-right shunting ﬂow across the superior limbus (between the 2 arrows) after
placement of dual transseptal catheter sheaths (c) for left atrial mapping and ablation. (C)
Variant Eustachian valve (arrow). (D) Color ﬂow (blue) showing ﬁlling from the RA to RV
during the cardiac cycle, not related to or directed by the variant Eustachian valve (arrow).
(E) An interatrial septal aneurysm bulging into the RA (red arrow), and a Chiari network
shown as a freely mobile, ﬁlamentous echodensity (white arrows) originating at the
junction of the inferior vena cava and RA. L ¼ implantable cardioverter-deﬁbrillator lead;
LA ¼ left atrium; PFO ¼ patent foramen ovale; RA ¼ right atrium; RV ¼ right ventricle; tv ¼
tricuspid valve.
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should be discussed and clariﬁed.
With routine clinical application of intracardiac
echocardiography (ICE) in more than 3,000 cases of
left heart ablation, it has been proven that ICE is an
excellent ultrasound modality that can be used for
diagnosis of an ASA, PFO, variant Eustachian valve,
or Chiari network (2). A statistical analysis of 938
consecutive cases with left heart ablation from 2012
to August 2014 showed that the incidence of ASA
was 6.9% and the incidence of PFO was 6.4%. A
variant Eustachian valve or Chiari network in the
right atrium is more commonly detected by routine
ICE. Generally speaking, ASA without a septal defect
and probe PFO should not be considered forms of an
atrial septal defect and are benign. By themselves,they cause no hemodynamic abnormalities. A pre-
vious case report (3) showed a small PFO (diameter
of <4 mm) with left to right shunting (Figure 2E in
the review by Windecker et al. [1]) and a transseptal
sheath for hemodynamic support with a left ven-
tricular assist device (the TandemHeart) (3). An iat-
rogenic PFO with large sheath placement at the
interatrial septum is commonly detected with ICE
monitoring (Figures 1A and 1B). In the case report
(3), the conclusion of “death by PFO” remains
questionable. Iatrogenic PFO (<4 mm) might not
be excluded, even in Figure 3 in the case report
(3), with a small/weak right-to-left shunt ﬂow
(not mosaic color pattern) accompanying the
transseptal sheath. A small PFO could not explain
that particular case, in which deep left femoral
vein thrombosis and bilateral subsegmental pulmo-
nary embolism advanced to myocardial embolic
infarction.
We disagree with the viewpoints of Windecker
et al. (1) on device closure in those with high-risk
criteria, including an ASA, PFO, Eustachian valve, or
Chiari network. We particularly dispute the idea that
a prominent Eustachian valve would direct blood
from the inferior vena cava toward the PFO; our
ﬁgure (Figures 1C and 1D) suggests that this is not the
case. ICE color Doppler ﬂow imaging is superior to
transient imaging with injected bubbles. The same
applies to the Chiari network in the right atrium with
chaotic motion (Figure 1E). Therefore, device closure
should not necessarily be considered in patients with
ﬁrst-time cryptogenic stroke who have these benign
variant anatomic abnormalities.*Jian-Fang Ren, MD
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